SINO BIOPHARM (01177) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 31.834 billion, representing a year-on-year increase of 10.25%. However, profit attributable to owners of the parent for the year was RMB 2.343 billion, a decrease of 33.04% compared to the previous year. Basic earnings per share were RMB 0.1302. The board proposed a final dividend of 5 Hong Kong cents per share.
According to the announcement, the group has officially entered a phase of intensive harvest from its innovative products, a result of years of sustained and increased investment in R&D. Over the past three years (2023-2025), the group secured approvals for a total of 16 innovative products, including seven Category 1 innovative drugs in China, leading the industry in the efficiency of translating innovative achievements into marketable products. This has driven the group's revenue to achieve double-digit growth for multiple consecutive years, with a growth rate significantly higher than the industry average.
During the reporting period, the group obtained approval from the National Medical Products Administration (NMPA) for four innovative products to be launched on the market. These are Saitansin® (Kumoxili Capsules), Shenghetu® (Zongaitinib Tablets), Putanning® (Meloxicam Injection (II)), and Anqixin® (Recombinant Human Coagulation Factor VIIa for Injection N01). Additionally, four new indications for three Category 1 innovative drugs received NMPA approval for market launch. These indications include anlotinib combined with bemosubai monoclonal antibody for first-line treatment of renal cell carcinoma, anlotinib combined with penpulimab for first-line treatment of hepatocellular carcinoma, anlotinib combined with chemotherapy for first-line treatment of soft tissue sarcoma, and penpulimab combined with chemotherapy for first-line treatment of nasopharyngeal carcinoma.
In 2025, revenue from the group's innovative products reached RMB 15.22 billion, a year-on-year increase of 26.2%. Research and development innovation remains the core driving force for the group. SINO BIOPHARM places high importance on R&D, considering it the cornerstone of sustainable development, and continues to increase R&D funding while striving to enhance R&D standards and efficiency. Currently, the group has established multiple R&D centers in cities including Shanghai, Nanjing, Beijing, and Guangzhou. It has successfully built a diversified innovation technology platform covering areas such as small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADCs), inhalation preparations, and transdermal patches.
For the year ended December 31, 2025, total R&D investment amounted to approximately RMB 6.317 billion, accounting for about 19.8% of the group's revenue. Approximately 92.9% of this R&D expenditure was recognized in the income statement.
Comments